The American Association of Colleges of Pharmacy (AACP) recently recognized a pharmacy educator from Midwestern University for his contributions to contemporary teaching and scholarship in biotechnology. Anil Gulati, M.D., Ph.D., Associate Dean, received the Paul R. Dawson Biotechnology Award during the Science Plenary at the AACP's Pharmacy Education 2014 meeting, in Grapevine, Texas in July.
"I'm so pleased to receive this award," Dr. Gulati said. "A lot of credit goes to my students who have contributed to my success and are now holding senior positions and making significant contributions in biotechnology."
Throughout his 35-year career, Dr. Gulati has made a lasting impact on student pharmacists, graduate students, postdoctoral researchers, medical fellows, and colleagues. "The Paul R. Dawson Biotechnology Award honoring Anil Gulati, M.D., is a testament to the excellent research, teaching, and mentoring he consistently provides to the students in the Chicago College of Pharmacy. The University takes great pride in his accomplishments as he represents our mission of excellence in healthcare," said Kathleen H. Goeppinger, Ph.D., President and Chief Executive Officer, Midwestern University.
As professor and associate dean of research at Midwestern University's Chicago College of Pharmacy, Dr. Gulati developed a popular elective course called Development of Newly Approved Drug Therapies. In this course, Gulati takes his students on a journey through the discovery, development, and approval process of biotechnology products. He also teaches a required first-year course, Biopharmaceutics and Pharmacokinetics, in which students learn about the factors that influence the absorption, distribution, bioavailability and pharmacokinetic variability of biotechnology products.
"Dr. Gulati sets high standards for his students, and then coaches and guides them to achieving those standards," said Nancy Fjortoft, Ph.D., Dean of the Chicago College of Pharmacy. "This truly exemplifies a great teacher."
Dr. Gulati is a nationally and internationally recognized expert in endothelin, which is a protein that constricts blood vessels and raises blood pressure. He has founded three pharmaceutical/biotechnology companies and as a result, some of his discoveries related to endothelin are undergoing clinical trials to translate into novel therapies in the areas of cancer treatment, neuroprotection, pain management and resuscitation from hemorrhagic shock. In 2007, Gulati received the International Ranbaxy Research Award and was a Fulbright Scholar in 2008-09.
The author of more than 285 peer-reviewed publications and recipient of 32 patents and inventions, Gulati says he is humbled to receive the Dawson award. He added, "It is a marvelous feeling to be listed among all those accomplished scientists and educators" who have previously received the award.